Question - PD-1/PD-L1 inhibitors have recently been approved for the treatment of a number of malignancies. The use of PD-1 axis inhibition is drastically changing the use of immunotherapy in cancer. What are the novel immune related adverse effects associated with the use of these agents?
Answer - The cited article notes “As PD-1/PD-L1 are involved in peripheral immune tolerance, inhibition of this immune checkpoint has led to novel immune-related adverse events including colitis, hepatitis, pneumonitis, rash, and endocrinopathies among many others.” (Hahn AW et al. PD-1 checkpoint inhibition: Toxicities and management. 2017 Urol Onc 35:701-707)